DLX1 and prostate carcinoma: In the van Neste et al. study, a clinically non-invasive test based on mRNA analysis of urinary biomarkers HOXC6 and DLX1 was developed and validated for the detection of clinically significant prostate cancer (Gleason ≥ 7).